ALL
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Conference Coverage
Phase 3 trial: Maribavir yields post-transplant benefits
Study findings “provide supportive evidence of the potential for long-term benefit” with maribavir for the treatment of post-transplant CMV.
From the Journals
“Terrific progress”: Adding blinatumomab for infant leukemia
Immunotherapy plus chemotherapy improves outcomes and may soon become first-line treatment for a rare pediatric blood cancer.
Conference Coverage
Phase 3 results: Ponatinib bests imatinib for Ph+ALL
First prospective study of third-generation TKI ponatinib showed its comparative benefit for the most common subtype of adult ALL.
Commentary
75 years: A look back on the fascinating history of methotrexate and folate antagonists
Dr. David Warmflash recounts how the meandering path of early research into chemotherapy for hematologic malignancies later led to methotrexate’s...
Feature
Mastocytosis: Rare, underdiagnosed, potentially fatal
This often-missed myeloid neoplasm could be deadly and deserves greater attention, experts say.
Feature
MD-researcher keeps her eyes on the prize
Researching CAR T-cell therapies for T-ALL, a physician-scientist works to saves children’s lives, as hers was saved.
Conference Coverage
Immunotherapy drug boosts survival in newly diagnosed ALL
First-line treatment with expensive medication should become standard, researcher says.
Conference Coverage
‘Clear answer’: ALL study defies conventional wisdom
Research on pediatric blood cancers found that high-dose methotrexate does not help cut the risk for central nervous system relapse.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
From the Journals
Novel co-admin of CAR T cells achieves 99% remission in leukemia
“We do believe [this approach] will become standard of care.”